Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques

R. Karl Malcolm, Ronald S. Veazey, Leslie Geer, Deborah Lowry, Susan M. Fetherston, Diarmaid J. Murphy, Peter Boyd, Ian Major, Robin J. Shattock, Per J. Klasse, Lara A. Doyle, Kelsi K. Rasmussen, Laurie Goldman, Thomas J. Ketas, John P. Moore

Research output: Contribution to journalArticle

Abstract

Antiretroviral entry inhibitors are now being considered as vaginally administered microbicide candidates for the prevention of the sexual transmission of human immunodeficiency virus. Previous studies testing the entry inhibitors maraviroc and CMPD167 in aqueous gel formulations showed efficacy in the macaque challenge model, although protection was highly dependent on the time period between initial gel application and subsequent challenge. In this paper, we describe the sustained release of maraviroc and CMPD167 from matrix-type silicone elastomer vaginal rings both in vitro and in vivo. Both inhibitors were released continuously during 28 days from rings in vitro at rates of 100 to 2,500 µg/day. In 28-day pharmacokinetic studies in rhesus macaques, the compounds were measured in the vaginal fluid and vaginal tissue; steady-state fluid concentrations were ~10(6)-fold greater than the 50% inhibitory concentrations (IC(50)s) for simian human immunodeficiency virus 162P3 inhibition in macaque lymphocytes in vitro. Plasma concentrations for both compounds were very low. The pretreatment of macaques with Depo-Provera (DP), which is commonly used in macaque challenge studies, was shown to significantly modify the biodistribution of the inhibitors but not the overall amount released. Vaginal fluid and tissue concentrations were significantly decreased while plasma levels increased with DP pretreatment. These observations have implications for designing macaque challenge experiments and also for ring performance during the human female menstrual cycle.
Original languageEnglish
Pages (from-to)2251-2258
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number5
Early online date13 Feb 2012
DOIs
Publication statusPublished - May 2012

Fingerprint

Female Contraceptive Devices
Macaca
Macaca mulatta
Medroxyprogesterone Acetate
Gels
HIV
Silicone Elastomers
Simian Immunodeficiency Virus
Menstrual Cycle
Anti-Infective Agents
Inhibitory Concentration 50
Pharmacokinetics
maraviroc
Lymphocytes
In Vitro Techniques

Cite this

Malcolm, R. K., Veazey, R. S., Geer, L., Lowry, D., Fetherston, S. M., Murphy, D. J., ... Moore, J. P. (2012). Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrobial Agents and Chemotherapy, 56(5), 2251-2258. https://doi.org/10.1128/AAC.05810-11
Malcolm, R. Karl ; Veazey, Ronald S. ; Geer, Leslie ; Lowry, Deborah ; Fetherston, Susan M. ; Murphy, Diarmaid J. ; Boyd, Peter ; Major, Ian ; Shattock, Robin J. ; Klasse, Per J. ; Doyle, Lara A. ; Rasmussen, Kelsi K. ; Goldman, Laurie ; Ketas, Thomas J. ; Moore, John P. / Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 5. pp. 2251-2258.
@article{b81cf600603f499ba1fa2d97f0f91c42,
title = "Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques",
abstract = "Antiretroviral entry inhibitors are now being considered as vaginally administered microbicide candidates for the prevention of the sexual transmission of human immunodeficiency virus. Previous studies testing the entry inhibitors maraviroc and CMPD167 in aqueous gel formulations showed efficacy in the macaque challenge model, although protection was highly dependent on the time period between initial gel application and subsequent challenge. In this paper, we describe the sustained release of maraviroc and CMPD167 from matrix-type silicone elastomer vaginal rings both in vitro and in vivo. Both inhibitors were released continuously during 28 days from rings in vitro at rates of 100 to 2,500 µg/day. In 28-day pharmacokinetic studies in rhesus macaques, the compounds were measured in the vaginal fluid and vaginal tissue; steady-state fluid concentrations were ~10(6)-fold greater than the 50{\%} inhibitory concentrations (IC(50)s) for simian human immunodeficiency virus 162P3 inhibition in macaque lymphocytes in vitro. Plasma concentrations for both compounds were very low. The pretreatment of macaques with Depo-Provera (DP), which is commonly used in macaque challenge studies, was shown to significantly modify the biodistribution of the inhibitors but not the overall amount released. Vaginal fluid and tissue concentrations were significantly decreased while plasma levels increased with DP pretreatment. These observations have implications for designing macaque challenge experiments and also for ring performance during the human female menstrual cycle.",
author = "Malcolm, {R. Karl} and Veazey, {Ronald S.} and Leslie Geer and Deborah Lowry and Fetherston, {Susan M.} and Murphy, {Diarmaid J.} and Peter Boyd and Ian Major and Shattock, {Robin J.} and Klasse, {Per J.} and Doyle, {Lara A.} and Rasmussen, {Kelsi K.} and Laurie Goldman and Ketas, {Thomas J.} and Moore, {John P.}",
year = "2012",
month = "5",
doi = "10.1128/AAC.05810-11",
language = "English",
volume = "56",
pages = "2251--2258",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

Malcolm, RK, Veazey, RS, Geer, L, Lowry, D, Fetherston, SM, Murphy, DJ, Boyd, P, Major, I, Shattock, RJ, Klasse, PJ, Doyle, LA, Rasmussen, KK, Goldman, L, Ketas, TJ & Moore, JP 2012, 'Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques', Antimicrobial Agents and Chemotherapy, vol. 56, no. 5, pp. 2251-2258. https://doi.org/10.1128/AAC.05810-11

Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. / Malcolm, R. Karl; Veazey, Ronald S.; Geer, Leslie; Lowry, Deborah; Fetherston, Susan M.; Murphy, Diarmaid J.; Boyd, Peter; Major, Ian; Shattock, Robin J.; Klasse, Per J.; Doyle, Lara A.; Rasmussen, Kelsi K.; Goldman, Laurie; Ketas, Thomas J.; Moore, John P.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 5, 05.2012, p. 2251-2258.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques

AU - Malcolm, R. Karl

AU - Veazey, Ronald S.

AU - Geer, Leslie

AU - Lowry, Deborah

AU - Fetherston, Susan M.

AU - Murphy, Diarmaid J.

AU - Boyd, Peter

AU - Major, Ian

AU - Shattock, Robin J.

AU - Klasse, Per J.

AU - Doyle, Lara A.

AU - Rasmussen, Kelsi K.

AU - Goldman, Laurie

AU - Ketas, Thomas J.

AU - Moore, John P.

PY - 2012/5

Y1 - 2012/5

N2 - Antiretroviral entry inhibitors are now being considered as vaginally administered microbicide candidates for the prevention of the sexual transmission of human immunodeficiency virus. Previous studies testing the entry inhibitors maraviroc and CMPD167 in aqueous gel formulations showed efficacy in the macaque challenge model, although protection was highly dependent on the time period between initial gel application and subsequent challenge. In this paper, we describe the sustained release of maraviroc and CMPD167 from matrix-type silicone elastomer vaginal rings both in vitro and in vivo. Both inhibitors were released continuously during 28 days from rings in vitro at rates of 100 to 2,500 µg/day. In 28-day pharmacokinetic studies in rhesus macaques, the compounds were measured in the vaginal fluid and vaginal tissue; steady-state fluid concentrations were ~10(6)-fold greater than the 50% inhibitory concentrations (IC(50)s) for simian human immunodeficiency virus 162P3 inhibition in macaque lymphocytes in vitro. Plasma concentrations for both compounds were very low. The pretreatment of macaques with Depo-Provera (DP), which is commonly used in macaque challenge studies, was shown to significantly modify the biodistribution of the inhibitors but not the overall amount released. Vaginal fluid and tissue concentrations were significantly decreased while plasma levels increased with DP pretreatment. These observations have implications for designing macaque challenge experiments and also for ring performance during the human female menstrual cycle.

AB - Antiretroviral entry inhibitors are now being considered as vaginally administered microbicide candidates for the prevention of the sexual transmission of human immunodeficiency virus. Previous studies testing the entry inhibitors maraviroc and CMPD167 in aqueous gel formulations showed efficacy in the macaque challenge model, although protection was highly dependent on the time period between initial gel application and subsequent challenge. In this paper, we describe the sustained release of maraviroc and CMPD167 from matrix-type silicone elastomer vaginal rings both in vitro and in vivo. Both inhibitors were released continuously during 28 days from rings in vitro at rates of 100 to 2,500 µg/day. In 28-day pharmacokinetic studies in rhesus macaques, the compounds were measured in the vaginal fluid and vaginal tissue; steady-state fluid concentrations were ~10(6)-fold greater than the 50% inhibitory concentrations (IC(50)s) for simian human immunodeficiency virus 162P3 inhibition in macaque lymphocytes in vitro. Plasma concentrations for both compounds were very low. The pretreatment of macaques with Depo-Provera (DP), which is commonly used in macaque challenge studies, was shown to significantly modify the biodistribution of the inhibitors but not the overall amount released. Vaginal fluid and tissue concentrations were significantly decreased while plasma levels increased with DP pretreatment. These observations have implications for designing macaque challenge experiments and also for ring performance during the human female menstrual cycle.

UR - http://www.scopus.com/inward/record.url?scp=84860210623&partnerID=8YFLogxK

UR - http://aac.asm.org/content/56/5/2251

U2 - 10.1128/AAC.05810-11

DO - 10.1128/AAC.05810-11

M3 - Article

C2 - 22330914

VL - 56

SP - 2251

EP - 2258

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -